JP5945554B2 - 縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター） - Google Patents

縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター） Download PDF

Info

Publication number
JP5945554B2
JP5945554B2 JP2013555597A JP2013555597A JP5945554B2 JP 5945554 B2 JP5945554 B2 JP 5945554B2 JP 2013555597 A JP2013555597 A JP 2013555597A JP 2013555597 A JP2013555597 A JP 2013555597A JP 5945554 B2 JP5945554 B2 JP 5945554B2
Authority
JP
Japan
Prior art keywords
pentalene
diaza
tetrahydro
oxy
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013555597A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506602A (ja
JP2014506602A5 (enExample
Inventor
アンソニー シー． ブラックバーン，
アンソニー シー． ブラックバーン，
サンドン ハン，
サンドン ハン，
ロバート エム． ジョンズ，
ロバート エム． ジョンズ，
アントニオ ガリド モンタルバン，
アントニオ ガリド モンタルバン，
バイマン ビー． パル，
バイマン ビー． パル，
ジェイミー カリン ロイター，
ジェイミー カリン ロイター，
Original Assignee
アリーナ ファーマシューティカルズ， インコーポレイテッド
アリーナ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリーナ ファーマシューティカルズ， インコーポレイテッド, アリーナ ファーマシューティカルズ， インコーポレイテッド filed Critical アリーナ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2014506602A publication Critical patent/JP2014506602A/ja
Publication of JP2014506602A5 publication Critical patent/JP2014506602A5/ja
Application granted granted Critical
Publication of JP5945554B2 publication Critical patent/JP5945554B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013555597A 2011-02-25 2012-02-24 縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター） Active JP5945554B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161446732P 2011-02-25 2011-02-25
US61/446,732 2011-02-25
US201161448542P 2011-03-02 2011-03-02
US61/448,542 2011-03-02
PCT/US2012/026506 WO2012116276A1 (en) 2011-02-25 2012-02-24 Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Publications (3)

Publication Number Publication Date
JP2014506602A JP2014506602A (ja) 2014-03-17
JP2014506602A5 JP2014506602A5 (enExample) 2015-04-16
JP5945554B2 true JP5945554B2 (ja) 2016-07-05

Family

ID=45841624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013555597A Active JP5945554B2 (ja) 2011-02-25 2012-02-24 縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター）

Country Status (20)

Country Link
US (4) US9458136B2 (enExample)
EP (3) EP3395812B8 (enExample)
JP (1) JP5945554B2 (enExample)
KR (1) KR102036932B1 (enExample)
CN (1) CN103608343B (enExample)
AU (1) AU2012222146B2 (enExample)
BR (1) BR112013021549B1 (enExample)
CA (1) CA2827057C (enExample)
CL (1) CL2013002436A1 (enExample)
CO (1) CO6852066A2 (enExample)
DK (1) DK3395812T3 (enExample)
EA (1) EA035989B1 (enExample)
ES (1) ES2932441T3 (enExample)
IL (1) IL227782A (enExample)
MX (1) MX346533B (enExample)
MY (1) MY165767A (enExample)
PH (1) PH12013501726A1 (enExample)
SG (1) SG192817A1 (enExample)
WO (1) WO2012116276A1 (enExample)
ZA (1) ZA201306402B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201404925TA (en) * 2009-08-28 2014-10-30 Arena Pharm Inc Cannabinoid receptor modulators
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CN103492369B (zh) * 2011-02-25 2019-03-29 艾尼纳制药公司 大麻素受体调节剂
EA035989B1 (ru) * 2011-02-25 2020-09-09 Арена Фармасьютикалз, Инк. Кристаллические формы и способы получения модуляторов каннабиноидного рецептора
WO2016085941A1 (en) * 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
MX2018012361A (es) * 2016-04-10 2019-05-30 Arena Pharm Inc Metodos de tratamiento con agonistas selectivos del receptor cb2.
EP3621619B1 (en) 2017-05-08 2023-06-28 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
WO2018208847A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
CN114391011A (zh) * 2019-09-12 2022-04-22 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
TW202330496A (zh) 2021-10-05 2023-08-01 美商艾尼納製藥公司 用於製備大麻素受體調節劑之結晶形式及方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
AU781266B2 (en) 1999-04-28 2005-05-12 Sanofi-Aventis Deutschland Gmbh Di-aryl acid derivatives as PPAR receptor ligands
WO2003049727A1 (en) 2001-12-07 2003-06-19 Virginia Commonwealth University Treatment of neoplasia
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
BRPI0513104A (pt) 2004-07-12 2008-04-29 Cadila Healthcare Ltd composto, composição farmacêutica, método para o tratamento de doenças associadas com os receptores de canabinóide, medicamento para o tratamento/redução de doenças associadas com os receptores de canabinóides, uso do composto, processo para a preparação do composto e intermediário
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
UA93390C2 (ru) * 2005-06-02 2011-02-10 Гленмарк Фармасьютикалс C.A. Лиганды каннабиноидных рецепторов, фармацевтическая композиция (варианты), которая их содержит, и способ их получения
CA2613678A1 (en) * 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
ATE459352T1 (de) 2006-07-04 2010-03-15 Janssen Pharmaceutica Nv Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe
KR20090069318A (ko) 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 조절하는 화합물
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
RU2009117203A (ru) 2006-11-03 2010-12-10 Гленмарк Фармасеутикалс С.А. (Ch) Новые лиганды каннабиноидных рецепторов, фармацевтические композиции, содержащие данные лиганды, и способы их получения
US8173638B2 (en) 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2008085302A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US20080161340A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof
WO2008109007A1 (en) 2007-03-02 2008-09-12 Cara Therapeutics, Inc. Bridged phenanthridines
WO2008114619A1 (ja) 2007-03-16 2008-09-25 Kyocera Corporation 誘電体磁器およびコンデンサ
ES2548764T3 (es) 2007-03-30 2015-10-20 Janssen Pharmaceutica N.V. Agonistas de cannabinoides de bencimidazol
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
JP5485148B2 (ja) 2007-06-21 2014-05-07 カラ セラピューティクス インコーポレイテッド 置換イミダゾ複素環
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
US20120004222A1 (en) 2007-08-21 2012-01-05 Zhicai Wu Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
US8653127B2 (en) 2009-01-28 2014-02-18 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
SG10201404925TA (en) * 2009-08-28 2014-10-30 Arena Pharm Inc Cannabinoid receptor modulators
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CN103492369B (zh) * 2011-02-25 2019-03-29 艾尼纳制药公司 大麻素受体调节剂
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EA035989B1 (ru) * 2011-02-25 2020-09-09 Арена Фармасьютикалз, Инк. Кристаллические формы и способы получения модуляторов каннабиноидного рецептора

Also Published As

Publication number Publication date
MY165767A (en) 2018-04-23
AU2012222146A1 (en) 2013-09-19
US10981895B2 (en) 2021-04-20
US20210380560A1 (en) 2021-12-09
EP4166552B1 (en) 2025-03-19
BR112013021549B1 (pt) 2022-01-11
US9458136B2 (en) 2016-10-04
US20170144993A1 (en) 2017-05-25
IL227782A0 (en) 2013-09-30
SG192817A1 (en) 2013-09-30
US11560369B2 (en) 2023-01-24
AU2012222146B2 (en) 2017-05-11
DK3395812T3 (da) 2022-11-28
EP3395812B8 (en) 2022-11-02
US20140135345A1 (en) 2014-05-15
CN103608343A (zh) 2014-02-26
NZ614787A (en) 2014-08-29
EA201391233A1 (ru) 2014-02-28
JP2014506602A (ja) 2014-03-17
US10183930B2 (en) 2019-01-22
EP3395812A1 (en) 2018-10-31
ES2932441T3 (es) 2023-01-19
CA2827057C (en) 2022-06-07
CL2013002436A1 (es) 2014-01-24
US20190308952A1 (en) 2019-10-10
BR112013021549A2 (pt) 2016-11-01
CO6852066A2 (es) 2014-01-30
IL227782A (en) 2017-02-28
PH12013501726A1 (en) 2014-01-13
WO2012116276A1 (en) 2012-08-30
ZA201306402B (en) 2022-03-30
EA035989B1 (ru) 2020-09-09
EP4166552A1 (en) 2023-04-19
KR20140025353A (ko) 2014-03-04
MX2013009760A (es) 2014-06-11
EP3395812B1 (en) 2022-09-28
MX346533B (es) 2017-03-14
KR102036932B1 (ko) 2019-10-25
CN103608343B (zh) 2019-02-01
EP2678330A1 (en) 2014-01-01
CA2827057A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
JP5945554B2 (ja) 縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター）
TWI503316B (zh) 類大麻酚受體調節劑
DE69425662T2 (de) Als heilmittel nutzbare piperazin verbindungen
JP2008504276A (ja) アミド化合物およびその医薬としての使用
JP2009535420A (ja) １１−βヒドロキシルステロイドデヒドロゲナーゼタイプ１のモジュレーターとしてのテトラ置換ウレア
CN103012378A (zh) 作为5-ht2a血清素受体调节剂适用于治疗与其相关的病症的3-苯基-吡唑衍生物
HK1263040A1 (en) Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
NZ614787B2 (en) Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
JPH07252218A (ja) ピロリジノン誘導体
WO2016085941A1 (en) Processes for the preparation of cannabinoid receptor modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20150929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160316

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160530

R150 Certificate of patent or registration of utility model

Ref document number: 5945554

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250